ClinicalTrials.gov
public full text
Public Domain
Biomarker-based Trial of NPC-1 for Alzheimer's Pathology
This early phase, open label, single arm clinical trial will determine the intraindividual safety, tolerability and effects of NPC1 (parthenolide and ipriflavone) on blood-based biomarkers of Alzheimer's disease (AD) pathology among adults with subjective cognitive decline, mild cognitive impairment, or Alzheimer's disease and objective indicators of seeding AD pathology
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Continuum of Core 1 biomarkers in preclinical Alzheimer's disease.#242159
- MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease#865253
- Amyloid-β Clearance Mechanisms in Alzheimer's Disease#1075278
- Plasma Biomarkers and Clinical Outcomes in Early-Onset Dementia.#148155
- Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium#1139100
Record · ID 897412
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive